ArticleMolecular medicine (Cambridge, Mass.)

Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.

Stephanie L Nott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.